Longeveron (LGVN) Net Cash Flow (QoQ) (2020 - 2026)
Longeveron (LGVN) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -151.19% |
| Mar 31, 2026 | 342.13% |
| Dec 31, 2025 | -320.46% |
| Sep 30, 2025 | 72.70% |
| Jun 30, 2025 | 18.59% |
| Mar 31, 2025 | -38.32% |
| Dec 31, 2024 | -134.09% |
| Sep 30, 2024 | -0.31% |
| Jun 30, 2024 | 446.79% |
| Mar 31, 2024 | -200.91% |
| Dec 31, 2023 | 482.31% |
| Sep 30, 2023 | 65.13% |
| Jun 30, 2023 | 59.47% |
| Mar 31, 2023 | -79.71% |
| Dec 31, 2022 | 53.82% |
| Sep 30, 2022 | -248.53% |
| Jun 30, 2022 | 45.89% |
| Mar 31, 2022 | -122.15% |
| Dec 31, 2021 | 324.38% |
| Sep 30, 2021 | -138.81% |